Skip to main content
. 2015 Mar 26;6(12):9970–9984. doi: 10.18632/oncotarget.3667

Figure 2. Delphinidin sensitizes LNCaP and Du145 cells with TRAIL-mediated apoptosis.

Figure 2

(A and B) Delphinidin has anti-proliferative and proapoptotic effects in prostate cancer cells. LNCaP and Du145 cells were treated with different concentration of delphinidin (DEL) (0, 30, 60, 90 μM) for 12 h. Delphinidin had no effect on cell viability at these concentrations as measured by an MTT assay (A) and western blot analysis against apoptosis marker PARP showed no cleavage (B). (C–F) Delphinidin sensitized LNCaP and Du145 cells to TRAIL-mediated apoptosis. LNCaP and Du145 cells were treated with different concentrations of delphinidin (0, 10, 30, 50 μM) and/or a fixed concentration of TRAIL (50 ng/ml) for 12 h. Combined treatment increased cell death as measured by an MTT assay (C) and PARP cleavage (D). Subsequently, LNCaP and Du145 cells were treated with different concentrations of TRAIL (0, 50, 100, 150 ng/ml) and a fixed concentration of delphinidin (30 μM) for 12 h. Combined treatment increased cell death (E) and PARP cleavage (F). The data are expressed as the mean ± SD for triplicates.